S&P 500   4,567.80 (+0.38%)
DOW   35,950.89 (+1.47%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
S&P 500   4,567.80 (+0.38%)
DOW   35,950.89 (+1.47%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
S&P 500   4,567.80 (+0.38%)
DOW   35,950.89 (+1.47%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
S&P 500   4,567.80 (+0.38%)
DOW   35,950.89 (+1.47%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)

Arvinas Stock Price, News & Analysis (NASDAQ:ARVN)

$21.97
-3.02 (-12.08%)
(As of 11/30/2023 ET)
Compare
Today's Range
$21.70
$24.54
50-Day Range
$14.19
$24.99
52-Week Range
$13.57
$42.52
Volume
1.39 million shs
Average Volume
472,877 shs
Market Capitalization
$1.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.77

Arvinas MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
135.6% Upside
$51.77 Price Target
Short Interest
Healthy
4.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.53mentions of Arvinas in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($5.26) to ($7.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

253rd out of 949 stocks

Pharmaceutical Preparations Industry

104th out of 437 stocks


ARVN stock logo

About Arvinas Stock (NASDAQ:ARVN)

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

ARVN Stock Price History

ARVN Stock News Headlines

Why Microsoft Just Placed A Huge Bet On Nuclear
Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.
Why Microsoft Just Placed A Huge Bet On Nuclear
Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.
Arvinas (NASDAQ:ARVN) Upgraded by Guggenheim to "Buy"
Guggenheim Upgrades Arvinas (ARVN)
Wedbush Upgrades Arvinas (ARVN)
Analyst Expectations for Arvinas's Future
Arvinas' Potential In Treating ER+, HER2- Breast Cancer
See More Headlines
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
415
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$51.77
High Stock Price Target
$95.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+135.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

Net Income
$-282,500,000.00
Net Margins
-185.09%
Pretax Margin
-175.38%

Debt

Sales & Book Value

Annual Sales
$131.40 million
Book Value
$8.31 per share

Miscellaneous

Free Float
53,623,000
Market Cap
$1.21 billion
Optionable
Not Optionable
Beta
1.86
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. John G. Houston Ph.D. (Age 63)
    Chairperson, CEO & President
    Comp: $1.08M
  • Dr. Ian Taylor Ph.D. (Age 60)
    Chief Scientific Officer
    Comp: $692k
  • Dr. Ronald A. Peck M.D. (Age 57)
    Chief Medical Officer
    Comp: $701.63k
  • Mr. David K. Loomis M.B.A. (Age 49)
    VP, Principal Accounting Officer & Chief Accounting Officer
  • Mr. Jeff Boyle
    Vice President of Investor Relations
  • Dr. Randy Teel Ph.D. (Age 44)
    Senior Vice President of Corporate & Business Development
  • Mr. Steve Weiss (Age 53)
    Senior VP & Chief Human Resources Officer
  • Dr. John A. Grosso Ph.D. (Age 66)
    Senior Vice President of R&D Technical Operations
  • Ms. Angela M. Cacace Ph.D. (Age 55)
    Senior Vice President of Neuroscience & Platform Biology
  • Mr. John P. Northcott (Age 45)
    Chief Commercial Officer














ARVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARVN shares.
View ARVN analyst ratings
or view top-rated stocks.

What is Arvinas' stock price target for 2024?

13 Wall Street research analysts have issued 12 month target prices for Arvinas' shares. Their ARVN share price targets range from $20.00 to $95.00. On average, they anticipate the company's stock price to reach $51.77 in the next twelve months. This suggests a possible upside of 135.6% from the stock's current price.
View analysts price targets for ARVN
or view top-rated stocks among Wall Street analysts.

How have ARVN shares performed in 2023?

Arvinas' stock was trading at $34.21 at the beginning of 2023. Since then, ARVN shares have decreased by 35.8% and is now trading at $21.97.
View the best growth stocks for 2023 here
.

Are investors shorting Arvinas?

Arvinas saw a decrease in short interest in November. As of November 15th, there was short interest totaling 2,140,000 shares, a decrease of 18.0% from the October 31st total of 2,610,000 shares. Based on an average trading volume of 491,800 shares, the days-to-cover ratio is presently 4.4 days. Approximately 4.5% of the company's shares are sold short.
View Arvinas' Short Interest
.

When is Arvinas' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our ARVN earnings forecast
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) posted its earnings results on Tuesday, November, 7th. The company reported ($1.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.58) by $0.40. The firm had revenue of $34.60 million for the quarter, compared to analysts' expectations of $39.58 million. Arvinas had a negative trailing twelve-month return on equity of 59.18% and a negative net margin of 185.09%. Arvinas's revenue for the quarter was up 14.2% on a year-over-year basis. During the same period last year, the company posted ($1.24) earnings per share.

What ETFs hold Arvinas' stock?
What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (8.85%), Avidity Partners Management LP (4.75%), JPMorgan Chase & Co. (3.61%), Northern Trust Corp (0.87%), Brown Advisory Inc. (0.81%) and Charles Schwab Investment Management Inc. (0.80%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon.
View institutional ownership trends
.

How do I buy shares of Arvinas?

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ARVN) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -